Effective December 1, 2016, all new Special Authorization requests for the treatment of Moderately to Severely Active Crohn’s Disease and Fistulizing Crohn’s Disease or Ulcerative Colitis for infliximab naive patients will be assessed for coverage with Inflectra. Remicade will not be approved for new infliximab starts for patients with the indications stated above; however, coverage for Remicade will continue for patients who are currently well maintained on Remicade and are considered a ‘responder’ as defined in criteria. Additionally, patients will not be permitted to switch from Inflectra to Remicade or vice versa, if previously trialed and deemed unresponsive to therapy.

For more information, please click on the following link.